Wrist MRI may spot hidden amyloid clumps without needles
NCT ID NCT05150353
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tested whether a special MRI scan of the wrist can detect amyloid deposits in people with systemic amyloidosis, a condition where abnormal proteins build up in organs. Researchers enrolled 128 adults, including patients with cardiac amyloidosis and healthy volunteers. The goal was to see if MRI mapping could non-invasively identify amyloid in the wrist, potentially offering a simpler way to diagnose the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a non-invasive way to detect amyloid deposits in the wrist, potentially aiding earlier diagnosis of systemic amyloidosis.
- What could go wrong
- This is an observational study, not a treatment trial. The MRI technique may not be accurate enough for routine use, and results may not apply to all types of amyloidosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Privé Paul d'Egine
Champigny-sur-Marne, 94500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive peptide spot hidden amyloid in the heart?
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- Heart imaging may reveal hidden clues in rare heart disease
- New scan spots hidden organ damage before symptoms start
- Hidden amyloid in heart valves: a new clue in aortic stenosis?
- Could a new drug slow lewy body dementia? phase 2 trial begins